{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:51:35Z","timestamp":1790297495516,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated motor sensory peripheral neuropathy that is rare in clinical practice. This treatment method aims to suppress potential immunopathology. Nocardiosis is a rare, destructive, opportunistic disease. We report a case of failed treatment of CIDP combined with pulmonary nocardiosis, and for the first time, we link these 2 diseases together.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 65-year-old man developed symmetrical limb weakness. Four months later, he was diagnosed with CIDP and started receiving glucocorticoid (GC) treatment. The disease progressed slowly and was treated with mycophenolate mofetil (MMF) in combination. He did not follow the doctor requirements for monthly follow-up visits, and the preventive medication for sulfamethoxazole\/trimethoprim was not strictly implemented. Two months after the combination therapy, the patient developed fever, coughing and sputum production, as well as fatigue and poor appetite. Based on imaging and etiological results, he was diagnosed with pulmonary nocardiosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Chronic inflammatory demyelinating polyneuropathy, pulmonary nocardiosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After treatment with antibiotics, the patient lung infection temporarily improved. However, the patient CIDP condition progressed, limb weakness worsened, respiratory muscle involvement occurred, and intravenous immunoglobulin (IVIG) was administered. However, there was no significant improvement in the condition, and the patient died.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>In this report, we present a case of a patient with CIDP and pulmonary nocardiosis. It is worth noting that in order to avoid the progression and recurrence of CIDP, we did not stop using related therapeutic drugs during the treatment process, the patient had repeatedly refused to use IVIG. Despite this, the patient condition worsened when lung inflammation improved, leading to persistent respiratory failure and ultimately death. Treatment contradictions, medication issues, and patient compliance issues reflected in this case are worth considering.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>For patients with CIDP receiving immunosuppressive therapy, attention should be paid to the occurrence and severity of Nocardia infection. Therefore, early detection and treatment are necessary. We need to pay attention to the compliance of patients with prophylactic use of antibiotics, strengthen the follow-up, and urge them to return to their appointments on time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000038544","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:11:02Z","timestamp":1718388662000},"page":"e38544","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Chronic inflammatory demyelinating polyneuropathy with pulmonary nocardiosis: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6882-5108","authenticated-orcid":false,"given":"Cheng","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Bethune International Peace Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"17562864231190549","DOI":"10.1177\/17562864231190549","article-title":"Impact of the updated chronic inflammatory demyelinating polyneuropathy guideline on everyday clinical practice.","volume":"16","author":"Muley","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision.","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/pn-2021-002991","article-title":"Treatment of CIDP.","volume":"23","author":"Fehmi","year":"2023","journal-title":"Pract Neurol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2174\/1381612828666220325102840","article-title":"Chronic inflammatory demyelinating polyneuropathy (CIDP): current therapies and future approaches.","volume":"28","author":"Sva\u010dina","year":"2022","journal-title":"Curr Pharm Des"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1229298","DOI":"10.3389\/fcimb.2023.1229298","article-title":"A complicated infection by cutaneous Nocardia wallacei and pulmonary Mycobacterium abscessus in a Chinese immunocompetent patient: a case report.","volume":"13","author":"Qin","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.mayocp.2018.03.026","article-title":"History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy.","volume":"93","author":"Dyck","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"R7-20250503","first-page":"50","article-title":"Gabapentin versus Pregabalin for management of chronic inflammatory demyelinating polyradiculoneuropathy.","volume":"10","author":"Rayani","year":"2021","journal-title":"Am J Neurodegener Dis"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-981-32-9636-7_21","article-title":"Chronic inflammatory demyelinating polyneuropathy.","volume":"1190","author":"Kuwabara","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment.","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"e01868","DOI":"10.1128\/AAC.01868-19","article-title":"Retrospective analysis of antimicrobial susceptibility profiles of Nocardia species from a tertiary hospital and reference laboratory, 2011 to 2017.","volume":"64","author":"Hamdi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2018.12.007","article-title":"Clinical features,identification,antimicrobial resistance patterns of Nocardia species in China:2009-2017.","volume":"94","author":"Huang","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/imj.14068","article-title":"Nocardiosis:7-year experience at an Australian tertiary hospital.","volume":"49","author":"Paige","year":"2019","journal-title":"Intern Med J"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"866420","DOI":"10.3389\/fpubh.2022.866420","article-title":"Case report: disseminated nocardiosis caused by nocardia vulneris in a patient with macroglobulinemia.","volume":"10","author":"Qiu","year":"2022","journal-title":"Front Public Health"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijid.2023.02.023","article-title":"Clinical characteristics, susceptibility profiles, and treatment of nocardiosis: a multicenter retrospective study in 2015-2021.","volume":"130","author":"Yang","year":"2023","journal-title":"Int J Infect Dis"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"e0156021","DOI":"10.1128\/spectrum.01560-21","article-title":"Epidemiology and antimicrobial resistance profiles of the nocardia species in China, 2009 to 2021.","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1128\/JCM.41.10.4497-4501.2003","article-title":"Nocardiosis: review of clinical and laboratory experience.","volume":"41","author":"Saubolle","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections.","volume":"10","author":"Baden","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cmi.2023.10.008","article-title":"Trimethoprim-sulfamethoxazole significantly reduces the risk of nocardiosis in solid organ transplant recipients: systematic review and individual patient data meta-analysis.","volume":"30","author":"Passerini","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"e15016","DOI":"10.1111\/ctr.15016","article-title":"Risk factors and prophylaxis for nocardiosis in solid organ transplant recipients: a nested case-control study.","volume":"37","author":"Yetmar","year":"2023","journal-title":"Clin Transplant"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/cid\/ciw241","article-title":"Nocardia infection in solid organ transplant recipients: a multicenter European case-control study.","volume":"63","author":"Coussement","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/514340","article-title":"Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study.","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27046","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy-diagnostic pitfalls and treatment approach.","volume":"63","author":"Stino","year":"2021","journal-title":"Muscle Nerve"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"421","DOI":"10.37201\/req\/132.2022","article-title":"Pulmonary nocardiosis after COVID-19 infection: case report and literature review.","volume":"36","author":"Ortiz","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanism of action.","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/ajhp\/54.3.285","article-title":"Mycophenolate mofetil: a unique immunosuppressive agent.","volume":"54","author":"Hood","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/jnnp.2009.177576","article-title":"Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy.","volume":"81","author":"Bedi","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-022-01222-x","article-title":"Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies.","volume":"19","author":"Briani","year":"2022","journal-title":"Neurotherapeutics"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.transproceed.2007.06.050","article-title":"The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.","volume":"39","author":"Carbone","year":"2007","journal-title":"Transplant Proc"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/jgid.jgid_93_19","article-title":"Intravenous immunoglobulin for overwhelming postsplenectomy infection.","volume":"13","author":"Nakamura","year":"2021","journal-title":"J Glob Infect Dis"},{"key":"R30-20250503","first-page":"CD000361","article-title":"Intravenous immunoglobulin for preventing infection in preterm and\/or low birth weight infants.","volume":"1","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hon.3185","article-title":"Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection-related hospitalizations in multiple myeloma patients.","volume":"41","author":"Sheu","year":"2023","journal-title":"Hematol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:43:08Z","timestamp":1746319388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038544","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}